Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)– Bristol-Myers
Squibb Company (NYSE:BMY) and Pfizer
Inc. (NYSE:PFE) today announced that eight abstracts have been
accepted for presentation at the American College of Cardiology (ACC) 66^th
Annual Scientific Session, taking place March 17-19 in Washington, D.C.
In addition to post-hoc analyses from the pivotal Phase 3 ARISTOTLE (Apixaban
for Reduction In STroke and Other ThromboemboLic Events
in Atrial Fibrillation) trial, the Bristol-Myers Squibb and Pfizer
Alliance will present real-world data analyses that illustrate the
Alliance’s ongoing commitment to understanding the use of direct oral
anticoagulants, including Eliquis™ (apixaban), in routine
clinical practice. This real-world research, part of the global
ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld
POpuLatIon Studies) program, aims to
complement findings from clinical trials and contribute to the growing
body of knowledge around anticoagulation.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170306005286/en/

In a Late-Breaking Clinical Trials session, the Alliance will highlight
a post-hoc analysis from the ARISTOTLE trial, titled ARISTOTLE:
Digoxin and Mortality in Patients with Atrial Fibrillation with and
without Heart Failure: Does Serum Digoxin Concentration Matter?
Results of the analysis will be presented on March 19 at 11:00 a.m.
Eastern Daylight Time.

“During ACC, the Bristol-Myers Squibb and Pfizer Alliance will share
several analyses that delve deeper into the robust data generated from
the ARISTOTLE study,” said Christoph Koenen, M.D., MBA, VP, Development
Lead, Eliquis, Bristol-Myers Squibb. “Through continued analyses
and support of the ARISTOTLE trial, we can examine topics such as
outcomes for patients with different comorbidities and the potential
treatment effects of interacting drugs, which expands our scientific
understanding.”

“As physicians evaluate options for reducing stroke risk in patients
with non-valvular atrial fibrillation, they often face questions about
the effectiveness and safety of therapies in day-to-day practice,” said
Rory O’Connor, M.D., Chief Medical Officer, Pfizer Innovative Health.
“Real-world data analyses allow us to explore the usage of Eliquis
and anticoagulants across various geographies and subgroups of patients.
Alongside clinical data, the real-world data analyses we are presenting
during ACC have the potential to help healthcare providers make more
informed decisions along with their patients.”

Below is a complete list of Bristol-Myers and Pfizer Alliance
presentations during ACC. Abstracts can be accessed through the ACC.17
Online Program Planner.

About Eliquis

Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By
inhibiting Factor Xa, a key blood clotting protein, Eliquis
decreases thrombin generation and blood clot formation. Eliquis is
approved for multiple indications in the U.S. based on efficacy and
safety data from seven Phase 3 clinical trials. Eliquis is a
prescription medicine indicated to reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation
(NVAF); for the prophylaxis of deep vein thrombosis (DVT), which may
lead to pulmonary embolism (PE), in patients who have undergone hip or
knee replacement surgery; for the treatment of DVT and PE; and to reduce
the risk of recurrent DVT and PE, following initial therapy.

ELIQUIS Important Safety Information

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK
OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

(A) Premature discontinuation of any oral anticoagulant, including
ELIQUIS, increases the risk of thrombotic events. If anticoagulation
with ELIQUIS is discontinued for a reason other than pathological
bleeding or completion of a course of therapy, consider coverage with
another anticoagulant.

(B) Epidural or spinal hematomas may occur in patients treated with
ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal
puncture. These hematomas may result in long-term or permanent
paralysis. Consider these risks when scheduling patients for spinal
procedures. Factors that can increase the risk of developing epidural or
spinal hematomas in these patients include:

• use of indwelling epidural catheters
• concomitant use of other drugs that affect hemostasis, such as
  nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors,
  other anticoagulants
• a history of traumatic or repeated epidural or spinal punctures
• a history of spinal deformity or spinal surgery
• optimal timing between the administration of ELIQUIS and neuraxial
  procedures is not known

Monitor patients frequently for signs and symptoms of neurological
impairment. If neurological compromise is noted, urgent treatment is
necessary.

Consider the benefits and risks before neuraxial intervention in
patients anticoagulated or to be anticoagulated.

CONTRAINDICATIONS

• Active pathological bleeding
• Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic
  reactions)

WARNINGS AND PRECAUTIONS

• Increased Risk of Thrombotic Events after Premature
  Discontinuation: Premature discontinuation of any oral
  anticoagulant, including ELIQUIS, in the absence of adequate
  alternative anticoagulation increases the risk of thrombotic events.
  An increased rate of stroke was observed during the transition from
  ELIQUIS to warfarin in clinical trials in atrial fibrillation
  patients. If ELIQUIS is discontinued for a reason other than
  pathological bleeding or completion of a course of therapy, consider
  coverage with another anticoagulant.
• Bleeding Risk: ELIQUIS increases the risk of bleeding and can
  cause serious, potentially fatal, bleeding.
  • Concomitant use of drugs affecting hemostasis increases the risk
    of bleeding, including aspirin and other antiplatelet agents,
    other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs,
    and NSAIDs.
  • Advise patients of signs and symptoms of blood loss and to report
    them immediately or go to an emergency room. Discontinue ELIQUIS
    in patients with active pathological hemorrhage.
  • There is no established way to reverse the anticoagulant effect of
    apixaban, which can be expected to persist for at least 24 hours
    after the last dose (i.e., about two half-lives). A specific
    antidote for ELIQUIS is not available.
• Spinal/Epidural Anesthesia or Puncture: Patients treated with
  ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop
  an epidural or spinal hematoma which can result in long-term or
  permanent paralysis.

  The risk of these events may be
  increased by the postoperative use of indwelling epidural catheters or
  the concomitant use of medicinal products affecting hemostasis.
  Indwelling epidural or intrathecal catheters should not be removed
  earlier than 24 hours after the last administration of ELIQUIS. The
  next dose of ELIQUIS should not be administered earlier than 5 hours
  after the removal of the catheter. The risk may also be increased by
  traumatic or repeated epidural or spinal puncture. If traumatic
  puncture occurs, delay the administration of ELIQUIS for 48 hours.

  Monitor
  patients frequently and if neurological compromise is noted, urgent
  diagnosis and treatment is necessary. Physicians should consider the
  potential benefit versus the risk of neuraxial intervention in ELIQUIS
  patients.

• Prosthetic Heart Valves: The safety and efficacy of ELIQUIS
  have not been studied in patients with prosthetic heart valves and is
  not recommended in these patients.
• Acute PE in Hemodynamically Unstable Patients or Patients who
  Require Thrombolysis or Pulmonary Embolectomy: Initiation of
  ELIQUIS is not recommended as an alternative to unfractionated heparin
  for the initial treatment of patients with PE who present with
  hemodynamic instability or who may receive thrombolysis or pulmonary
  embolectomy.

ADVERSE REACTIONS

• The most common and most serious adverse reactions reported with
  ELIQUIS were related to bleeding.

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

• ELIQUIS should be discontinued at least 48 hours prior to elective
  surgery or invasive procedures with a moderate or high risk of
  unacceptable or clinically significant bleeding. ELIQUIS should be
  discontinued at least 24 hours prior to elective surgery or invasive
  procedures with a low risk of bleeding or where the bleeding would be
  noncritical in location and easily controlled. Bridging
  anticoagulation during the 24 to 48 hours after stopping ELIQUIS and
  prior to the intervention is not generally required. ELIQUIS should be
  restarted after the surgical or other procedures as soon as adequate
  hemostasis has been established.

DRUG INTERACTIONS

• Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of
  cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) increase
  exposure to apixaban and increase the risk of bleeding. For patients
  receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose
  of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are
  strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole,
  itraconazole, ritonavir, or clarithromycin). In patients already
  taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with
  strong dual inhibitors of CYP3A4 and P-gp.
• Strong Dual Inducers of CYP3A4 and P-gp: Avoid concomitant use
  of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g.,
  rifampin, carbamazepine, phenytoin, St. John’s wort) because such
  drugs will decrease exposure to apixaban and increase the risk of
  stroke and other thromboembolic events.
• Anticoagulants and Antiplatelet Agents: Coadministration of
  antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic
  NSAID use increases the risk of bleeding. APPRAISE-2, a
  placebo-controlled clinical trial of apixaban in high-risk post-acute
  coronary syndrome patients treated with aspirin or the combination of
  aspirin and clopidogrel, was terminated early due to a higher rate of
  bleeding with apixaban compared to placebo.

PREGNANCY CATEGORY B

• There are no adequate and well-controlled studies of ELIQUIS in
  pregnant women. Treatment is likely to increase the risk of hemorrhage
  during pregnancy and delivery. ELIQUIS should be used during pregnancy
  only if the potential benefit outweighs the potential risk to the
  mother and fetus.

Please see full Prescribing Information, including BOXED WARNINGS and
Medication Guide, available at www.bms.com.

About ACROPOLIS™

ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld
POpuLatIon Studies) is the Eliquis
(apixaban) global real-world data program designed to generate
additional evidence from routine clinical practice settings to further
inform healthcare decision makers, including healthcare providers and
payers. The ACROPOLIS program will include retrospective, outcomes-based
analyses from over 10 databases around the world, including medical
records, medical and pharmacy health insurance claims data, and national
health data systems.

Analyses of real-world data allow for a broader understanding of patient
outcomes associated with Eliquis outside of the clinical trial
setting, as well as insight into other measures of healthcare delivery,
such as hospitalization and costs.

About ARISTOTLE

ARISTOTLE (Apixaban for Reduction In STroke
and Other ThromboemboLic Events in Atrial
Fibrillation) was designed to evaluate the efficacy and safety of Eliquis
versus warfarin for the prevention of stroke or systemic embolism. In
ARISTOTLE, 18,201 patients were randomized (9,120 patients to Eliquis
and 9,081 to warfarin). ARISTOTLE was an active-controlled, randomized,
double-blind, multi-national trial in patients with nonvalvular atrial
fibrillation or atrial flutter, and at least one additional risk factor
for stroke. Patients were randomized to treatment with Eliquis 5
mg orally twice daily (or 2.5 mg twice daily in selected patients,
representing 4.7 percent of all patients) or warfarin (target INR range
2.0-3.0), and followed for a median of 1.8 years.

About the Bristol-Myers Squibb/Pfizer Collaboration

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide
collaboration to develop and commercialize apixaban, an oral
anticoagulant discovered by Bristol-Myers Squibb. This global alliance
combines Bristol-Myers Squibb’s long-standing strengths in
cardiovascular drug development and commercialization with Pfizer’s
global scale and expertise in this field.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
YouTube
and Facebook.

About Pfizer Inc.: Working together for a healthier world^®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and @PfizerNews,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains « forward-looking statements » as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding product development. Such forward-looking statements are based
on current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb’s
business, particularly those identified in the cautionary factors
discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the
year ended December 31, 2016, in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise.

Pfizer Disclosure Notice

The information contained in this release is as of March 6, 2017.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future
events or developments.

This release contains forward-looking information about Eliquis
(apixaban), including its potential benefits, that involves substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties inherent in
research and development, including, without limitation, the ability to
meet anticipated clinical trial commencement and completion dates as
well as the possibility of unfavorable clinical trial results, including
unfavorable new clinical data and additional analyses of existing
clinical data; decisions by regulatory authorities regarding labeling
and other matters that could affect the availability or commercial
potential of Eliquis; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2016 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the SEC
and available at www.sec.gov
and www.pfizer.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005286/en/